We used a mouse model of ccRCC to demonstrate proof-of-principle that anti-CAIX CAR T cells armed to deliver immuno-modulatory mAbs at the tumor site were superior to parental anti-CAIX CAR T cells in their ability to be resistant to exhaustion both in vitro and in vivo. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.